New Combination Builds Upon Existing Therapies for Anaplastic Astrocytoma
Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.
Arati Desai, MD, co-director of the University of Pennsylvania Brain Tumor Cancer Program Center and assistant professor of Clinical Medicine, at the Perelman School of Medicine, University of Pennsylvania, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma (AA).
When treatment advances are sought, the therapies that are needed are those that improve upon the standard of care. There are good agents available for the treatment of AA, but the drugs are older and, at times, cause intolerable toxicity and offer limited benefit.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Olaptesed Pegol Wins FDA Fast Track Designation in Brain Cancer
April 3rd 2024The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.
Read More
